Australian rare disease company Percheron Therapeutics has provided an update on its ongoing international phase 2b clinical trial of ATL1102 in Duchenne muscular dystrophy.
The company said that at the end of March, 34 out of a total target of 45 patients had been randomised and had initiated treatment. An additional 7 patients are currently in screening or anticipated to commence screening shortly, and it is expected that the majority will be randomised in the coming weeks.
The company said it is working closely with sites to identify further patients, and recruitment is expected to be completed soon. To date, 9 patients have successfully transitioned into the open-label extension phase of the study, in which all patients receive ATL1102. No patients have withdrawn from the study.
"We continue to make steady progress with recruiting the study," commented Percheron CEO Dr James Garner. "It is disappointing that we still have a few more patients to enrol, but our priority is naturally to ensure that all patients meet the strict eligibility criteria and that the study is conducted exactly in accordance with the protocol. At this stage, we continue to expect data in 2H CY2024, as previously indicated."
